Table 3.
VEGF genotype and allele frequency in patients with cSCC (n=100) and control (n=124).
| Groups | Controls (n=124) | Patients (n=100) | P-value* | OR (95% CI) | P-value# |
|---|---|---|---|---|---|
| -1154460 C>T | |||||
| CC | 51 (41.13%) | 65 (65.00%) | – | 1.00 (reference) | – |
| CT | 63 (50.81%) | 31 (31.00%) | 0.001 | 0.39 (0.22–0.68) | 0.043 |
| TT | 10 (8.06%) | 4 (4.00%) | 0.052 | 0.31 (0.09–1.06) | 0.715 |
| TT+CT | 73 (58.87%) | 35 (35.00%) | <0.001 | 0.36 (0.21–0.63) | <0.001 |
| Allele frequency | |||||
| C | 165 (66.53%) | 161 (80.50%) | – | 1.00 (reference) | – |
| T | 83 (33.47%) | 39 (19.50%) | 0.001 | 0.48 (0.31–0.75) | – |
| -11541154 G>A | |||||
| GG | 54 (43.55%) | 51 (51.00%) | – | 1.00 (reference) | – |
| GA | 58 (46.77%) | 41 (41.00%) | 0.305 | 0.75 (0.43–1.30) | 0.247 |
| AA | 12 (9.68%) | 8 (8.00%) | 0.482 | 0.71 (0.27–1.87) | 0.654 |
| GA+AA | 70 (56.45%) | 49 (49.00%) | 0.267 | 0.74 (0.44–1.26) | 0.155 |
| Allele frequency | |||||
| G | 166 (66.94%) | 143 (71.50%) | – | 1.00 (reference) | – |
| A | 82 (33.06%) | 57 (28.50%) | 0.299 | 0.81 (0.54–1.21) | – |
VEGF – vascular endothelial growth factor; OR – odds ratio; CI – confidence interval.
*
Two-sided χ2 test for distribution of genotypic and allelic frequencies.
#
Compared by binary logistic multivariate regression model with adjustment of sex and age for cases and controls.